Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

44.25 -0.18 (-0.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,054,349
Open 44.84
Bid (Size) 44.25 (2)
Ask (Size) 44.30 (3)
Prev. Close 44.43
Today's Range 43.50 - 45.14
52wk Range 30.04 - 63.68
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering
FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research 
Via Benzinga
Exposures Product Safety
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation. 
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety

Performance

YTD
+6.8%
+6.8%
1 Month
+12.7%
+12.7%
3 Month
+7.5%
+7.5%
6 Month
+9.2%
+9.2%
1 Year
-25.8%
-25.8%

More News

Read More
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
Via Benzinga
Jabil Posts Upbeat Earnings, Joins Verve Therapeutics, John Wiley & Sons And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
Via Investor's Business Daily
Cathie Wood Just Flagged The Start Of A Biotech Revolution: These 2 Stocks With 10x Potential Are Leading It
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
The Best Stocks to Invest $1,000 in Right Now
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip
Via The Motley Fool
Topics Economy
Exposures Economy
5 Monster Stocks to Hold for the Next 10 Years
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy?
Via The Motley Fool
Exposures Product Safety
Prediction: This Beaten-Down Stock Could Double in The Next 5 Years
Via The Motley Fool
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise
Via MarketBeat
Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics?
Via The Motley Fool
2 Biotech Stocks That Are Screaming Buys in May
Via The Motley Fool
Can Buying CRISPR Therapeutics and Holding It Forever Make You a Millionaire?
Via The Motley Fool
3 Monster Stocks to Hold for the Next 10 Years
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Via The Motley Fool
Topics Artificial Intelligence World Trade
Exposures Artificial Intelligence Tariff
CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst
Via Benzinga
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
Via Benzinga
Exposures Product Safety
These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results
Via Benzinga
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Vertex Pharmaceuticals Topples 12% On A Series Of First-Quarter Setbacks
Via Investor's Business Daily
Topics Government Intellectual Property
Exposures Intellectual Property Political
Cathie Wood Sells Palantir Shares Worth $2.65 Million Ahead Of Earnings, Doubles Down On This Chip Giant
Via Benzinga
2 Beaten-Down Stocks With Incredible Upside Potential
Via The Motley Fool
5 Monster Stocks -- Such as Coupang -- to Hold for the Next 10 Years
Via The Motley Fool
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy

Frequently Asked Questions

Is CRISPR Therapeutics AG - Common Shares publicly traded?
Yes, CRISPR Therapeutics AG - Common Shares is publicly traded.
What exchange does CRISPR Therapeutics AG - Common Shares trade on?
CRISPR Therapeutics AG - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for CRISPR Therapeutics AG - Common Shares?
The ticker symbol for CRISPR Therapeutics AG - Common Shares is CRSP on the Nasdaq Stock Market
What is the current price of CRISPR Therapeutics AG - Common Shares?
The current price of CRISPR Therapeutics AG - Common Shares is 44.25
When was CRISPR Therapeutics AG - Common Shares last traded?
The last trade of CRISPR Therapeutics AG - Common Shares was at 06/20/25 04:00 PM ET
What is the market capitalization of CRISPR Therapeutics AG - Common Shares?
The market capitalization of CRISPR Therapeutics AG - Common Shares is 3.49B
How many shares of CRISPR Therapeutics AG - Common Shares are outstanding?
CRISPR Therapeutics AG - Common Shares has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.